GRDNHealthcare · Medical Care FacilitiesGRDN Stock Forecast: Guardian Pharmacy Services, Inc. Price Predictions for 2026-2027
The 6 Wall Street analysts covering Guardian Pharmacy Services, Inc. hold a median 12-month price target of $47 — +15.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 1 Aug 2026 — in the upper half. Here, the model and the Street point the same way.
GRDN stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Guardian Pharmacy Services, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (94): The shares have been drifting up relative to others.
Value (24): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Guardian Pharmacy Services, Inc. — and when they’d sell — is the membership.
GRDN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on GRDN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +15.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 June 2026 | B of A Securities | Maintains | Buy | $42 → $47 |
| 17 June 2026 | Truist Securities | Maintains | Buy | $43 → $47 |
| 7 May 2026 | Oppenheimer | Maintains | Outperform | — |
| 27 Apr 2026 | B of A Securities | Initiates | Buy | — |
| 13 Apr 2026 | Truist Securities | Maintains | Buy | — |
| 30 Mar 2026 | Jefferies | Initiates | Buy | — |
| 12 Mar 2026 | Oppenheimer | Maintains | Outperform | — |
| 12 Mar 2026 | Truist Securities | Maintains | Buy | — |
| 14 Jan 2026 | Stephens & Co. | Maintains | Overweight | — |
| 14 Nov 2025 | Truist Securities | Maintains | Buy | — |
| 10 Oct 2025 | Oppenheimer | Initiates | Outperform | — |
| 26 Sept 2025 | Truist Securities | Maintains | Buy | — |
| 19 May 2025 | Truist Securities | Reiterates | Buy | — |
| 11 Apr 2025 | Truist Securities | Maintains | Buy | — |
| 15 Nov 2024 | Truist Securities | Maintains | Buy | — |
| 22 Oct 2024 | Stephens & Co. | Initiates | Overweight | — |
| 21 Oct 2024 | Truist Securities | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
GRDN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Guardian Pharmacy Services, Inc. (GRDN) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 47.1×
- Price / sales
- 1.7×
- Price / book
- 11.3×
- EV / EBITDA
- 22.5×
Cheaper than 16% of US stocks
Cheaper than 57% of US stocks
Cheaper than 9% of US stocks
Cheaper than 14% of US stocks
- Revenue growth (YoY)
- 2.2%
- Earnings growth (YoY)
- 40.7%
- Gross margin
- 22.7%
- Operating margin
- 6.2%
- Net margin
- 3.6%
Higher than 34% of US stocks
Higher than 74% of US stocks
Higher than 26% of US stocks
Higher than 60% of US stocks
Higher than 56% of US stocks
- Return on equity
- 26.9%
- Return on assets
- 14.4%
- Dividend yield
- —
Higher than 86% of US stocks
Higher than 97% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
GRDN vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GRDN appears on the weeks it earns a place.
Frequently asked questions about GRDN stock
What is the GRDN stock price forecast for 2026-2027?
The 6 Wall Street analysts covering Guardian Pharmacy Services, Inc. have a median 12-month price target of $47, with estimates ranging from $43 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is GRDN stock a buy right now?
Of the 6 analysts covering Guardian Pharmacy Services, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Guardian Pharmacy Services, Inc. 71 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank GRDN?
As at 1 Aug 2026, Guardian Pharmacy Services, Inc. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).
Will GRDN stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts implies +15.2% from the last close, and Ticker Nerd's factor model ranks Guardian Pharmacy Services, Inc. 71 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the GRDN stock forecast for 2030?
No analyst covering Guardian Pharmacy Services, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GRDN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $43 to $50 over the next 12 months.
How has GRDN stock performed over the past year?
Guardian Pharmacy Services, Inc. returned +100.7% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Guardian Pharmacy Services, Inc. do?
Guardian Pharmacy Services Inc. is a company that provides comprehensive pharmacy services primarily focused on the long-term care and senior living sectors.
About Guardian Pharmacy Services, Inc.
Guardian Pharmacy Services Inc. is a company that provides comprehensive pharmacy services primarily focused on the long-term care and senior living sectors. Its primary function is to ensure the safe, efficient, and timely delivery of medications to residents in assisted living facilities, nursing homes, and other similar communities. Notable features of Guardian Pharmacy Services include personalized care plans, innovative pharmacy technology solutions, and a strong emphasis on regulatory compliance and medication safety. The company employs a collaborative approach, working closely with caregivers, healthcare professionals, and facility administrators to optimize pharmaceutical care outcomes. Guardian's services significantly impact the health management sector, contributing to improved quality of life for residents through tailored medication management systems. With a growing network of independent local pharmacies across the U.S., Guardian Pharmacy Services plays a vital role in the healthcare industry, addressing the unique needs of its clientele through specialization and dedicated service provision. The company's efforts in enhancing operational efficiencies and adopting advanced pharmacy practices underscore its market significance in delivering indispensable healthcare support.
CEO Mr. Fred P. Burke · 3,600 employees · United States · https://guardianpharmacy.com